The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder
Acad Emerg Med
.
2023 Dec;30(12):1285-1287.
doi: 10.1111/acem.14814.
Epub 2023 Oct 28.
Authors
Jake R Morgan
1
,
Sabrina A Assoumou
2
Affiliations
1
Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts, USA.
2
Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
PMID:
37793818
PMCID:
PMC10841521
DOI:
10.1111/acem.14814
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
MeSH terms
Analgesics, Opioid / therapeutic use
Humans
Opioid-Related Disorders* / drug therapy
Substances
Analgesics, Opioid
Grants and funding
R01 DA046527/DA/NIDA NIH HHS/United States
P30 DA040500/DA/NIDA NIH HHS/United States
R01DA046527/DA/NIDA NIH HHS/United States
P30DA040500/DA/NIDA NIH HHS/United States
K23 DA044085/DA/NIDA NIH HHS/United States
K23DA044085/DA/NIDA NIH HHS/United States
K23DA044085/DA/NIDA NIH HHS/United States
P30DA040500/DA/NIDA NIH HHS/United States
R01DA046527/DA/NIDA NIH HHS/United States